Crl4crbn e3 ligase complex as a therapeutic target in multiple myeloma

HIGHLIGHTS

  • who: Joanna Barankiewicz and colleagues from the Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland have published the research: CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma, in the Journal: Cancers 2022, 4492 of /2022/
  • what: The PROTAC technique does not require binding to the target protein`s active_site, so this approach has a great advantage in overcoming the potential limitations of classical small-molecule protein inhibitors (transient targeting of non-covalent inhibitors; resistance caused by protein overexpression or point mutations).
  • future: As IMiDs resistance is one . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?